Brivaracetam Pharmaceutical API
Pharmaceutical Premium
Pharmaceutical API

Brivaracetam

High-purity pharmaceutical grade Brivaracetam API manufactured to meet stringent USP/EP specifications for antiepileptic medication production. Our pharmaceutical-grade Brivaracetam delivers exceptional quality and consistency for critical pharmaceutical applications.

  • USP/EP Compliant Grade
  • High Purity (>99.5%)
  • Antiepileptic Drug
  • GMP Certified Manufacturing
  • Reliable Supply Chain
  • Complete Documentation
Request Quote Technical Support

Technical Specifications

Chemical Formula: C11H20N2O2
CAS Number: 357336-20-0
Molecular Weight: 212.29 g/mol
Purity (HPLC): ≥99.5% (pharmaceutical grade)
Physical State: White to off-white crystalline powder
Water Content (Karl Fischer): ≤0.5%
Residue on Ignition: ≤0.1%
Heavy Metals (as Pb): ≤10 ppm
Related Substances: ≤0.5% total impurities
Storage Conditions: Store in cool, dry place (15-30°C)
Packaging Options: 1kg, 5kg pharmaceutical containers

Applications

Antiepileptic Drug Manufacturing
Neurological Health Formulations
Oral Pharmaceutical Products
API Synthesis & Development
Epilepsy Treatment Research
Pharmaceutical Research
Drug Product Manufacturing
Quality Control Testing
Regulatory Compliance
Clinical Trial Materials
Bioanalytical Method Development
Reference Standard Applications

Industry-Specific Grades

DRAVYOM offers specialized Brivaracetam grades tailored for specific pharmaceutical requirements, ensuring optimal performance and regulatory compliance across diverse antiepileptic drug manufacturing applications.

USP Grade (Pharmaceutical)
Purity: ≥99.5% (HPLC) Water Content: ≤0.5% Heavy Metals: ≤10 ppm Application: Pharmaceutical formulations
EP Grade (European Pharmacopoeia)
Purity: ≥99.5% (pharmaceutical) Related Substances: ≤0.5% Residue on Ignition: ≤0.1% Application: European market compliance
Research Grade
Purity: ≥98.0% (analytical) Water Content: ≤1.0% Particle Size: Controlled Application: R&D, method development
GMP Grade
Purity: ≥99.8% (pharmaceutical) Endotoxins: ≤2.5 EU/mg Microbial Limits: Compliant Application: Antiepileptic formulations

Quality Standards

DRAVYOM's pharmaceutical grade Brivaracetam is manufactured under stringent cGMP protocols, meeting international pharmaceutical standards including USP, EP, and ICH guidelines. Our pharmaceutical-grade production ensures consistent quality and regulatory compliance.

cGMP Certified Manufacturing
USP/EP Grade Specifications
≥99.5% Pharmaceutical Purity
Advanced Analytical Testing
Comprehensive Impurity Control
Batch-to-Batch Consistency
Complete Documentation Package
Temperature-Controlled Logistics

Advanced Chemical Properties & Performance

Pharmaceutical grade Brivaracetam exhibits exceptional chemical properties essential for antiepileptic applications. Its ultra-pure composition and precise molecular structure ensure reliable performance in demanding pharmaceutical formulations and research applications.

Analytical Properties
Solubility (Water): Freely soluble
LogP (octanol/water): 0.7
pKa: Not applicable
UV λmax: 254 nm
Physical Properties
Melting Point: 63-65°C
Bulk Density: 0.5-0.7 g/mL
Crystalline Form: White to off-white crystalline powder
Hygroscopicity: Non-hygroscopic
Pharmaceutical Performance
Bioavailability: 100% (oral)
Protein Binding: 20%
Half-life: 9 hours
Elimination: Renal excretion
Purity Specifications
Assay (HPLC): ≥99.5%
Related Substances: ≤0.5% total
Water Content: ≤0.5% (Karl Fischer)
Residue on Ignition: ≤0.1%
Stability Properties
Shelf Life: 3 years (unopened)
Light Sensitivity: Protect from light
Temperature Stability: Stable 15-30°C
Container Compatibility: HDPE, glass containers

Performance Characteristics

Detailed performance metrics demonstrate pharmaceutical grade Brivaracetam superiority in antiepileptic applications with exceptional synaptic vesicle protein binding, CNS penetration, and reproducibility across diverse pharmaceutical formulations and neurological therapeutic protocols.

SV2A Binding

High affinity for synaptic vesicle protein 2A

Selective antiepileptic mechanism
Formulation Stability

Stable in oral solid dosage forms

Excellent pharmaceutical stability
Bioavailability

100% oral bioavailability achieved

Complete absorption characteristics
Temperature Stability

Stable under ambient conditions

Consistent performance 15-30°C
Batch Reproducibility

Variation: ±0.3% between batches

Exceptional lot-to-lot consistency
Shelf Stability

3 years under proper storage conditions

Extended pharmaceutical grade integrity

Safety Information

Handle with standard pharmaceutical safety precautions. Use appropriate personal protective equipment including safety goggles, gloves, and protective clothing. Avoid inhalation of powder and ensure adequate ventilation in work areas. Follow established pharmaceutical handling protocols.

Caution
Avoid Inhalation
Wear Gloves

Storage & Handling

Store in original containers in a cool, dry place protected from light and moisture. Keep containers tightly closed and maintain pharmaceutical storage conditions. Use appropriate handling equipment and ensure controlled environment.

Store at 15-30°C
Protect from light
Protect from moisture
Keep containers tightly closed

Chemical Mechanisms & Reaction Pathways

Brivaracetam exhibits selective antiepileptic properties through high-affinity binding to synaptic vesicle protein 2A (SV2A), enabling predictable therapeutic response with well-characterized pharmacokinetic and pharmacodynamic profiles.

Mechanism of Action

High-affinity binding to synaptic vesicle protein 2A (SV2A)

Targeted seizure control mechanism
Metabolic Pathway

Hepatic metabolism via CYP2C19 and hydrolysis

Predictable drug interaction profile
Pharmacokinetics

100% oral bioavailability with 7-8 hour half-life

Suitable for twice-daily dosing
Elimination

Primarily renal excretion of metabolites

Standard elimination pathways

Regulatory Compliance & Documentation

Comprehensive regulatory compliance ensures global pharmaceutical market access with complete documentation packages supporting international drug registration and regulatory submissions.

USP Monograph

United States Pharmacopeia specifications compliance

EP Standards

European Pharmacopoeia monograph requirements

cGMP Manufacturing

Current Good Manufacturing Practices compliance

ICH Guidelines

International Council for Harmonisation standards

DMF Support

Drug Master File documentation assistance

Audit Readiness

Regulatory inspection preparation and support

Technical Support & Value-Added Services

DRAVYOM's pharmaceutical development team provides comprehensive formulation support, regulatory guidance, and technical services to optimize Brivaracetam performance in your specific pharmaceutical applications.

Formulation Development
  • Excipient compatibility studies
  • Stability testing protocols
  • Dissolution optimization
  • Bioavailability enhancement
Analytical Services
  • Method validation support
  • Impurity identification
  • Stability indicating methods
  • Pharmaceutical testing
Technical Support
  • Regulatory compliance guidance
  • Quality assurance protocols
  • Manufacturing process support
  • Documentation preparation
Supply Solutions
  • Pharmaceutical grade scheduling
  • Global regulatory shipping
  • Custom packaging options
  • Emergency supply protocols

Environmental Impact & Sustainability

Our Brivaracetam production emphasizes environmental responsibility through sustainable pharmaceutical manufacturing practices, waste minimization, and comprehensive environmental impact management.

Waste Minimization

Optimized synthesis with minimal pharmaceutical waste

Water Treatment

Advanced wastewater treatment and recycling systems

Clean Production

Energy-efficient synthesis with emission controls

Safe Disposal

Pharmaceutical waste management guidance

ISO 14001

Environmental management system certification

Green Chemistry

Sustainable pharmaceutical synthesis methods

Manufacturing Excellence & Quality Control

DRAVYOM's state-of-the-art pharmaceutical manufacturing facility employs advanced synthesis technology and continuous monitoring systems to ensure consistent Brivaracetam quality and performance across all production batches.

cGMP Production

Current Good Manufacturing Practices in controlled pharmaceutical environment

FDA and WHO-GMP certified facility
Quality Testing

Comprehensive pharmaceutical testing including identity, purity, and potency

USP/EP monograph compliance verification
Quality Systems

ISO 9001:2015 with pharmaceutical quality management

Continuous improvement and validation
Packaging Control

Pharmaceutical-grade packaging with moisture protection

Stability and contamination prevention

Market Applications & Performance Data

Comprehensive pharmaceutical data demonstrating Brivaracetam effectiveness across diverse therapeutic applications with quantified performance metrics and clinical validation.

Pharmaceutical Formulations
Bioavailability: 100% oral absorption Half-life: 7-8 hours therapeutic duration Stability: 3+ years shelf life
Clinical Applications
Efficacy: 50% seizure reduction rate Safety: Well-tolerated CNS profile Dosage: 50-200mg daily therapeutic range
Manufacturing Data
Purity: >99.5% pharmaceutical grade Consistency: ±0.3% batch variation Yield: >95% synthesis efficiency

DRAVYOM Competitive Advantages

Pharmaceutical Excellence

Consistently exceeds USP/EP specifications with exceptional pharmaceutical quality and performance

Reliable Supply

Guaranteed pharmaceutical-grade availability with cGMP production scheduling

Development Expertise

Dedicated pharmaceutical development team providing formulation and regulatory support

Quality Assurance

Comprehensive COA with pharmaceutical testing and regulatory compliance documentation

Global Standards

International compliance with USP, EP, and ICH guidelines for worldwide market access

Partnership Approach

Collaborative relationships with pharmaceutical companies and custom API development